Abstract

Viatris Inc. will report its first-quarter 2026 results Pre-Market on May 7, 2026, and this preview outlines consensus expectations for revenue and EPS, last quarter’s margin and earnings setup, key business drivers for the quarter, and where analysts are leaning ahead of the print.

Market Forecast

Consensus for the first quarter of 2026 points to revenue of 3.36 billion US dollars, up 3.77% year over year, adjusted EPS of 0.50 per share, up 2.61% year over year, and EBIT of 834.97 million US dollars, down 0.36% year over year; formal gross margin and net margin projections are not disclosed in the consolidated estimates. Operationally, the company continues to emphasize branded execution and demand resilience in Greater China and Emerging Markets, with incremental contribution expected from new product launches; among growth vectors, new products added 78.00 million US dollars in the prior quarter, and management has guided to 0.45 billion to 0.55 billion US dollars of new product revenue in 2026.

Last Quarter Review

In the fourth quarter of 2025, Viatris Inc. delivered revenue of 3.70 billion US dollars, up 4.97% year over year, a gross profit margin of 40.31%, a GAAP net loss attributable to shareholders of 0.34 billion US dollars with a net margin of -9.18%, and adjusted EPS of 0.57, up 5.56% year over year. Despite the adjusted outperformance, GAAP profitability registered a loss, and the quarter-on-quarter net profit growth rate declined by 165.29% as reflected in the reported metric, while the company highlighted strong execution on brands and continued capital deployment to shareholders. Main business highlights included better performance in Greater China and Emerging Markets that supported the company-wide revenue increase to 3.70 billion US dollars, up 4.97% year over year, with new product launches adding 78.00 million US dollars in the quarter.

Current Quarter Outlook

Core Commercial Franchise

The company’s first quarter is set against a backdrop of stabilizing top-line dynamics and an emphasis on execution in its core commercial franchise. The revenue consensus of 3.36 billion US dollars implies steady year-over-year growth of 3.77%, which is aligned with the company’s full-year 2026 revenue outlook ranging from 14.45 billion to 14.95 billion US dollars. That run-rate suggests the first quarter will be an important baseline for the year’s shape, particularly with respect to volume trends in key geographies that drove the prior quarter’s beat. Margin watchers will focus on the interplay between price, mix, and ongoing cost actions. While consensus margin estimates are not broadly published for the quarter, management has a multi-year cost efficiency program targeting 650.00 million US dollars in gross savings over three years. This program supports the case for margin stabilization through 2026 even as the product mix remains in transition, and should be especially visible in operating expense discipline. Within branded and established products, the quarter is expected to reflect the same steady demand seen in the fourth quarter, particularly in geographies that delivered robust performance previously. The consistency of this base is essential for supporting the earnings bridge to the guided full-year range. Given the first quarter’s modest growth expectations, investors are likely to judge execution on the quality of revenue and the clarity of how mix and savings will defend gross and operating margin through midyear.

Largest Growth Opportunity

New product launches represent the clearest incremental growth lever for 2026, with management guiding to 0.45 billion to 0.55 billion US dollars of new product revenue for the year. In the fourth quarter of 2025, new launches contributed 78.00 million US dollars, helping to offset pressures in older product lines and to signal the trajectory that management intends to build upon this year. While quarterly contributions can be lumpy, the first quarter is a relevant checkpoint for assessing whether the new launch cadence is tracking toward the annual range. The upcoming product flow also includes potential catalysts that extend beyond the quarter. The United States regulator has accepted the supplemental filing for a presbyopia candidate (with a Prescription Drug User Fee Act date set for October 17, 2026), which, if ultimately approved, would expand the company’s presence in eye care and potentially contribute to medium-term brand momentum. Although that catalyst sits outside the current quarter, investors may use management’s commentary to calibrate timelines, launch preparedness, and eventual market access strategy. Commercial execution partnerships can also support growth levers. The recent collaboration to offer discounts on 17 brand medicines through a national savings platform could broaden patient access in cash-pay channels and support brand volumes across retail pharmacies. The immediate revenue impact in the first quarter is unlikely to be the primary driver, but the initiative underscores management’s focus on affordability and reach, which can compound over several quarters as awareness and pharmacy adoption scale.

Key Stock Price Drivers This Quarter

The near-term share reaction will likely hinge on whether the company confirms the first-quarter run-rate consistent with the full-year revenue outlook and provides evidence of margin discipline. Investors will parse qualitative commentary on price/volume dynamics in performance geographies that supported the fourth-quarter result, looking for signs of persistence or normalization in demand patterns. Any detail on the pace and phasing of the 650.00 million US dollars cost-savings program would help frame operating leverage into the second half. New product execution is the other decisive near-term factor. Tracking the quarter’s contribution from recent launches to ensure visibility toward 0.45 billion to 0.55 billion US dollars for 2026 will shape expectations for the back half. Management’s color on further launches, manufacturing readiness, and channel access will inform whether incremental revenue can exceed the current quarter’s modest growth assumption and whether mix can gradually support margin. Capital allocation also remains in focus following greater than 1.00 billion US dollars returned to shareholders in 2025. Investors will look for updates on the quarterly cadence of repurchases or dividends, the balance with deleveraging, and how management prioritizes cash uses alongside potential pipeline or portfolio investments. Beyond the print, any legal or regulatory developments, including updates related to historical litigation or portfolio rationalization, could affect sentiment around earnings quality, but the near-term bar is more about operational consistency and clear guidance confirmation.

Analyst Opinions

Across the views collected during the period from January 1, 2026 to April 30, 2026, the balance of opinion is decisively bullish: 100% of the referenced published calls are positive (Barclays, Jefferies, Truist Financial, and UBS), with no bearish recommendations cited in the same window. Barclays, led by Glen Santangelo, reiterates a Buy with a 17.00 US dollars price target, emphasizing the company’s execution on earnings, visibility on new product contribution, and room for operating efficiency gains to underpin the margin profile. Jefferies maintains a Buy rating with a 17.00 US dollars target, highlighting that the quarterly consensus—3.36 billion US dollars of revenue and 0.50 US dollars adjusted EPS—appears achievable given the fourth-quarter momentum and the supportive trajectory of the 2026 outlook. Truist Financial reiterates a Buy with an 18.00 US dollars target, pointing to the multi-year cost-savings framework of 650.00 million US dollars and an expanding pipeline that together improve the case for earnings durability. The firm’s stance is that near-term revenue growth, while modest at 3.77% for the quarter, can be paired with expense discipline to deliver consistent adjusted EPS performance, keeping first-quarter numbers within reach. UBS upgrades to Buy with an 18.00 US dollars target, citing improving earnings visibility, a clearer capital returns framework, and progress on long-term objectives such as free cash flow expansion and revenue compounding through 2030. Putting these threads together, the bullish case synthesizes to three elements relevant to the coming print. First, the fourth-quarter delivery established a sturdier base—3.70 billion US dollars of revenue, 40.31% gross margin, and 0.57 US dollars adjusted EPS—against which the first-quarter consensus looks balanced. Second, the cumulative impact of new product launches, evidenced by 78.00 million US dollars in the prior quarter and the full-year 2026 contribution target of 0.45 billion to 0.55 billion US dollars, offers incremental top-line support that can offset legacy erosion. Third, the company’s cost agenda and capital deployment discipline are expected to help hold the earnings line even if product mix creates temporary noise in margin optics. Analysts generally expect management to reaffirm the path consistent with the 14.45 billion to 14.95 billion US dollars full-year revenue outlook while guiding investors through the quarterly cadence of new product ramp and cost savings. On the quarter itself, the prevailing view is that a delivery near 3.36 billion US dollars of revenue and around 0.50 US dollars adjusted EPS, with stable operating trends in core geographies, would be sufficient to sustain positive sentiment. The majority also underscore that clarity on the distribution of new product revenue across quarters and confirmation that expense actions are tracking to plan would raise confidence in the second-half setup. In short, the majority opinion anticipates a steady first quarter with balanced execution that keeps the full-year framework intact, and positions the story for improving free cash flow and earnings quality as 2026 progresses.